Masonic Cancer Center, University of Minnesota: Ovarian Neoplasms trials

The registry lists 14 Ovarian Neoplasms studies with Masonic Cancer Center, University of Minnesota as lead sponsor. 1 are open to participants now and 9 have results posted.

Phase 1 6Phase 2 4No phase 4(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• UNTOLD Ovarian Cancer Unmet Needs SurveyRecruitingNCT07070726
• MT2021-27 FT538 Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal CancerTerminatedNCT05708924Phase 1Results posted
• Assessing the Time Demands of CancerActive, not recruitingNCT05708703Results posted
• FT516 and IL2 With Enoblituzumab for Ovarian CancerCompletedNCT04630769Phase 1Results posted
• IP ALT-803 Followed by SQ ALT-803 for Ovarian CancerCompletedNCT03054909Phase 2Results posted
• WCC# 59 Hyperthermic Intraperitoneal Chemotherapy Utilizing Carboplatin in First Recurrence Ovarian CancerTerminatedNCT01144442Not applicableResults posted
• Allogeneic Natural Killer (NK) Cells for Ovarian, Fallopian Tube, Peritoneal and Metastatic Breast CancerCompletedNCT01105650Phase 2Results posted
• Allogeneic Natural Killer Cells in Patients With Recurrent Ovarian Cancer, Fallopian Tube, and Primary Peritoneal CancerTerminatedNCT00652899Phase 2Results posted
• Study of Immune Response Modifier in the Treatment of Breast, Ovarian, Endometrial and Cervical CancersCompletedNCT00319748Phase 2Results posted
• Outcomes in Ovarian Cancer and Fallopian Tube Cancer Patients Using Complementary Alternative MedicineCompletedNCT00293293Not applicableResults posted
• Intraperitoneal FT536 in Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal CancerActive, not recruitingNCT06342986Phase 1
• Intraperitoneal Natural Killer Cells and INCB024360 for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal CancerCompletedNCT02118285Phase 1
• Bortezomib and Gemcitabine in Treating Older Patients With Advanced Solid TumorsCompletedNCT00620295Phase 1
• Topotecan in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity CancerTerminatedNCT00287859Phase 1